The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Adrianus De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Nong Yang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma
 
Sang-We Kim
No Relationships to Disclose
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Steven Chuan-Hao Kao
Leadership - Thoracic Oncology Group Australia
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Elevation Oncology; GlaxoSmithKline; Merck; Merus; Taiho Oncology
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Denis Lucien MORO SIBILOT
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly O.; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - MSD
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly O.; MSD; Pfizer; Roche; Sanofi; Takeda
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline (Inst); Janssen; Lilly; Merck Sharp & Dohme; Novartis (Inst); Pfizer (Inst); Roche/Genentech; Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Matthew G Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen
Speakers' Bureau - Janssen; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep
 
Parneet Kaur Cheema
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Janssen Oncology; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Janssen Oncology; Merck; Novartis; Novartis; Pfizer; Roche
 
Christophe Alfons Dooms
No Relationships to Disclose
 
Shanna Stopatschinskaja
Employment - Turning Point Therapeutics
Stock and Other Ownership Interests - Turning Point Therapeutics
 
Denise Trone
Employment - Bristol-Myers Squibb
 
Felipe Ades
Employment - Bristol-Myers Squibb
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)